Cempra Pharmaceuticals completes its Series A round
Executive Summary
Cempra Pharmaceuticals (developing therapeutics to treat drug-resistant bacteria in the hospital and at home) has raised $22mm with its Series A venture round. Intersouth Partners and I. Wistar Morris, III (an investment banker) co-led the financing and were joined by new backer Aisling Capital.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice